5 citations
,
January 2021 in “Inflammatory Bowel Diseases” Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
5 citations
,
February 1997 in “Bioorganic & Medicinal Chemistry” New compounds were made that effectively block a specific enzyme related to androgen conditions.
May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly”
January 2024 in “Journal of Crohn's and colitis” Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
October 2022 in “Journal of experimental and clinical medicine” Repurposing existing drugs for COVID-19 shows promise but requires more research to confirm effectiveness.
20 citations
,
July 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Six existing drugs may help block virus entry in COVID-19.
November 2023 in “Journal of Cosmetic Dermatology” Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.
May 2024 in “JAMA Dermatology” Oral contraceptive use may increase the risk of frontal fibrosing alopecia in women with a specific CYP1B1 gene variant.
16 citations
,
August 2002 in “Journal of Interferon and Cytokine Research” A man developed excessive hair growth after treatment with interferon-alpha and ribavirin for hepatitis C.
3 citations
,
April 2021 in “Oncology Times” Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
February 2026 in “Indian Journal of Dermatology” Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.
17 citations
,
August 2007 in “Bioorganic & Medicinal Chemistry Letters” A compound made by Pfizer can potentially stimulate hair growth and reduce oil production, making it a good candidate for topical use.
5 citations
,
January 2022 in “Dermatology Reports” Tofacitinib treatment for hair loss may worsen acne.
November 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Five FDA-approved drugs may help block COVID-19 virus entry.
January 2025 in “Journal of Crohn s and Colitis” Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
5 citations
,
September 2020 in “Proceedings - Baylor University. Medical Center” Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.
The document's conclusion cannot be provided because the document is not available or cannot be read.
20 citations
,
January 1995 in “Journal of Dermatological Science” Cyclosporin A and FK506 can start new hair growth without needing immunosuppression.
January 2011 in “Annals of dermatology/Annals of Dermatology” A woman's psoriasis improved after hepatitis C treatment with interferon, despite interferon's risk of worsening skin conditions.
2 citations
,
January 2014 in “Advanced Biomedical Research” Oral isotretinoin and cyproterone compound are equally effective for treating acne in women with cutaneous hyperandrogenism.
July 2025 in “Journal of Cosmetic Dermatology” Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.
1 citations
,
December 2004 in “Hepatology” Tenofovir is more effective than adefovir for resistant hepatitis B, Fibroscan is good for assessing liver damage, regulatory T cells may help hepatitis C persist, and other insights into liver health and disease were found.
August 2020 in “Ugeskrift for Læger” A man with severe hair loss regrew all his hair using tofacitinib and stayed healthy for a year.
49 citations
,
March 2017 in “Journal of the American Academy of Dermatology” Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
5 citations
,
July 2007 in “PubMed” An HIV patient's complete hair loss was reversed after switching from lopinavir/ritonavir to nelfinavir.
15 citations
,
December 2019 in “European Journal of Dermatology” Low-dose tofacitinib is effective and cheaper for severe alopecia areata.
December 1989 in “Inpharma (Balgowlah)” Cyproterone helps women with hair loss caused by genetics. More research is needed to confirm the best dose.
1 citations
,
September 2022 in “Sudan Journal of Medical Sciences” Danoprevir, remdesivir, and saridegib may effectively inhibit SARS-CoV-2.
13 citations
,
February 2017 in “Clinical rheumatology” Tofacitinib may help treat nail dystrophy, especially when other treatments fail.